Details for Patent: 6,090,799

US Patent 6,090,799: Scope, Claim-by-Claim Coverage, and US Patent Landscape for Orally Administered Oxandrolone for HIV-Associated Myopathy

US Drug Patent 6,090,799 claims methods that use oxandrolone (an oral anabolic steroid) to ameliorate HIV-associated myopathy and muscle weakness / muscle wasting in AIDS patients, under defined daily dose and treatment duration parameters. The patent’s enforceable scope is limited to method claims (not product/composition claims) and is tightly constrained by (i) patient population, (ii) route (oral), (iii) drug identity (oxandrolone), (iv) dose range, and (v) duration (about 2 weeks).

What do the claims actually cover? (Scope map)

Claim set (as provided)

Claim 1

• Method for ameliorating HIV-associated myopathy and muscle weakness in an AIDS patient
• Includes: orally administering oxandrolone
• Daily dose: between about 2.5 mg and about 7.5 mg

Claim 2

• Depends on claim 1
• Daily dose: about 7.5 mg

Claim 3

• Depends on claim 1
• Unit-dose schedule: 1 to 2.5 mg three times per day
• Timing: about 8-hour intervals

Claim 4

• Depends on claim 1
• Dosage form: tablet

Claim 5 and 6

• Depends on claim 1
• Duration: about 2 weeks
• (Same text appears twice in the provided claims.)

Claim 7

• Depends on claim 3
• Duration: about 2 weeks

Claim 8

• Independent (as provided)
• Method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient
• Includes: orally administering a therapeutically effective amount of oxandrolone daily
• Duration: about 2 weeks

Enforceable core

The “center of mass” of the patent is:

• Oral oxandrolone
• for HIV-associated myopathy manifested as muscle weakness/wasting
• in AIDS patients
• with a 2.5 to 7.5 mg/day daily dosing window (claim 1)
• typically run for about 2 weeks (claims 5-7 and 8)

Boundary conditions that matter for infringement analysis

The claims impose explicit limits that define both direct infringement risk and design-around space:

• Patient type: “AIDS patient.” If a label/clinical protocol targets HIV patients without “AIDS” clinical status, risk depends on factual medical characterization and how “AIDS patient” is construed.
• Indication/phenotype: “HIV-associated myopathy” with weakness or wasting. Protocols for general cachexia without myopathy, or myopathy not “HIV-associated,” are outside the claim language.
• Route: “Orally administering.” Any non-oral route (injectable oxandrolone formulations, if any) avoids the literal “oral” requirement.
• Drug identity: “oxandrolone.” Substitution with another anabolic steroid is not captured by these method claims.
• Dose: claim 1 is bounded by 2.5 to 7.5 mg/day.
• Duration: claim 5-7 and 8 require about 2 weeks. Longer regimens are not automatically excluded, but would need careful analysis against “about” and claim construction.

Claim-by-claim scope and practical coverage

Claim 1: Daily dose window + oral route + AIDS myopathy

Text constraints

• Oral oxandrolone
• Daily dosage: 2.5 to 7.5 mg/day
• Intended therapeutic effect: ameliorate HIV-associated myopathy and muscle weakness
• Applies to an AIDS patient

Practical interpretation

• Any clinical protocol that administers oral oxandrolone within that daily dose window for the stated disease target would fall within claim 1, assuming factual match to “AIDS patient” and “HIV-associated myopathy and muscle weakness.”

Claim 2: Specific daily dose cap (7.5 mg/day)

Text constraints

• Narrows claim 1 to: about 7.5 mg/day

Practical interpretation

• Higher-risk when the protocol uses the top end of the window.

Claim 3: Three-times-daily schedule

Text constraints

• Oral oxandrolone
• 1 to 2.5 mg per unit dose
• three times per day
• about 8-hour intervals
• Depends on claim 1 (so daily total still sits within 2.5 to 7.5 mg/day)

Practical interpretation

• The schedule is an additional limitation. A protocol using the same daily total but different dosing frequency could avoid literal coverage for claim 3 while still potentially implicating claim 1.

Claim 4: Tablet dosage form

Text constraints

• Depends on claim 1
• Oxandrolone administered as a tablet

Practical interpretation

• If oxandrolone is administered in a non-tablet oral dosage form (e.g., different solid form, distinct oral formulation) literal coverage would depend on whether that form is still “a tablet.” Claim 1 remains a fallback for oral administration regardless of dosage form, so claim 4 is a narrowing element.

Claims 5 and 6: Treatment duration “about 2 weeks”

Text constraints

• Depends on claim 1
• Administration continued about 2 weeks

Practical interpretation

• These claims add a duration requirement. A protocol that treats for substantially less than 2 weeks may avoid these dependent claims while still potentially infringing claim 1 (if claim 1 is considered independently). If all asserted claims require “about 2 weeks,” duration becomes the central design-around lever.

Claim 7: Schedule + 2-week duration

Text constraints

• Depends on claim 3
• Schedule: claim 3’s dosing pattern
• Duration: about 2 weeks

Practical interpretation

• The most structured protocol: three-times-daily unit dosing at 8-hour intervals plus a two-week treatment period.

Claim 8: Therapeutically effective amount + oral daily dosing + about 2 weeks

Text constraints

• Independent (as provided)
• Ameliorate HIV-associated myopathy and muscle wasting
• AIDS patient
• Oral oxandrolone, therapeutically effective amount
• Daily dosing
• Duration: about 2 weeks

Practical interpretation

• Claim 8 can be broader than claim 1 because it does not specify the explicit 2.5 to 7.5 mg/day range. It hinges on what qualifies as a “therapeutically effective amount” for the claimed indication and duration. In practice, many regimens that align with oxandrolone standard dosing for cachexia/myopathy could be treated as falling within the “therapeutically effective amount” standard if they are used for the claimed condition.

How does the claim architecture affect enforcement?

Independent vs dependent claim strength

• Claim 1 and claim 8 act as independent anchors (based on the claim set you provided).
• Claims 2-7 add narrower constraints (daily dose at 7.5 mg, specific scheduling, tablet form, and two-week duration).

Likely assertion patterns (practical risk)

• If a generic or investigator protocol matches dose/duration/schedule closely, the patentee can assert claim 1 (dose window) and dependent claims 3 and/or 5-7 if schedule and duration match.
• Claim 8 offers an enforcement path even if the daily dose is argued outside claim 1’s numeric window, as long as it is “therapeutically effective” and used for HIV-associated myopathy with muscle wasting in an AIDS patient for about 2 weeks.

Design-around surfaces

Based on the literal text provided, the easiest design-around levers are:

1. Avoid “AIDS patient” categorization by using protocols in a different disease stage classification (but enforceability would turn on factual medical status).
2. Avoid “HIV-associated myopathy” by targeting different indications.
3. Avoid oral administration.
4. Avoid the two-week treatment window (for dependent claims and for claim 8).
5. Use a non-tablet oral formulation to avoid claim 4 (but claim 1 and 8 may still remain).
6. Use different anabolic agents (oxandrolone identity is required).

US patent landscape: where infringement risk concentrates

You provided the claims but not the bibliographic metadata (filing date, expiration date, or family members). Without that metadata, a full “expiration-to-ANDA/505(b)(2) pipeline” analysis cannot be constructed accurately. The claim text still allows a high-confidence map of what types of US filings and scientific protocols will intersect with this patent.

Intersections to monitor in US patent filings and regulatory practice

Focus on US documentation that describes:

• Oxandrolone used orally
• specifically for HIV-associated myopathy, muscle weakness, or muscle wasting
• in AIDS clinical populations
• with dosing around 2.5 to 7.5 mg/day or in “therapeutically effective” amounts
• with treatment duration around two weeks

Likely adjacent patent categories in the US landscape

Even with only the claim text, the landscape typically clusters into:

• Method-of-treatment patents tied to:
  • HIV-associated wasting/myopathy
  • AIDS-related weakness syndromes
  • anabolic steroid dosing regimens and durations
• Formulation and dosage form patents:
  • oral solid dosage forms (tablet/capsule)
  • release profiles (if any exist)
• Use and dosing patents:
  • “daily dosing” and schedule constraints
  • “about X weeks” duration regimes

Where generics typically generate risk

This patent is a method claim. Generic oxandrolone products can still trigger method claim risk if the generic’s prescribing information, clinical protocols, or actual use practices in trials align with the claimed method. The practical risk for a competitor drug program is highest when:

• the competitor plans a study or label claim that administers oral oxandrolone to AIDS patients for HIV-associated myopathy symptoms, and
• the program uses dosing in the numeric window or a two-week regimen.

Scope vs related claim phrasing: “weakness” vs “wasting”

A key structural nuance:

• Claim 1 targets “muscle weakness.”
• Claim 8 targets “muscle wasting.”

Both are tied to “HIV-associated myopathy” and both require “AIDS patient” and “orally administering oxandrolone” for about 2 weeks (claim 8 expressly; dependent claims do for the claim 1 path).

In practical terms, this lets a patentee argue coverage across clinical endpoints labeled as weakness and muscle loss.

Enforcement-relevant claim elements checklist

Key takeaways

• US 6,090,799 is a method-of-treatment patent centered on oral oxandrolone for HIV-associated myopathy in AIDS patients, with explicit attention to dose (2.5 to 7.5 mg/day) and duration (about 2 weeks).
• Claim 1 provides a numeric daily dosing window (2.5 to 7.5 mg/day) for ameliorating muscle weakness.
• Claim 8 can be broader on dosing because it uses “therapeutically effective amount,” while still requiring daily dosing and about 2 weeks for muscle wasting.
• Dependent claims narrow scope via 7.5 mg/day, a three-times-daily schedule at ~8-hour intervals, tablet form, and two-week administration.
• In the US patent landscape, the highest intersection risk sits in method claims and trial protocols describing oral oxandrolone for AIDS-associated HIV myopathy/wasting with dosing and duration aligned to the patent’s constraints.

FAQs

1) Is US 6,090,799 a composition patent or a method patent?
It is a method patent, covering “a method for ameliorating” HIV-associated myopathy in AIDS patients using orally administered oxandrolone at specified dosing and duration parameters (claims as provided).

2) What is the key numeric dosing range in the strongest dose-anchored claim?
Claim 1 requires 2.5 to 7.5 mg/day of oxandrolone, orally administered (claim 1 as provided).

3) Does the patent require “about 2 weeks” for all claims?
No. The “about 2 weeks” limitation is explicit in claims 5-7 and in claim 8. It is not explicitly stated in claim 1’s text as provided, though dependent claims incorporate the duration.

4) Can a protocol outside 2.5 to 7.5 mg/day still infringe?
Yes, via claim 8, because it uses a “therapeutically effective amount” standard while still requiring oral daily oxandrolone for about 2 weeks for HIV-associated myopathy with muscle wasting in an AIDS patient (claim 8 as provided).

5) What design-around levers are directly supported by the claim language?
Switching away from oral oxandrolone, changing dose and/or duration so it is not “about 2 weeks,” avoiding the clinical target of AIDS HIV-associated myopathy with weakness/wasting, or changing the dosing schedule and dosage form to avoid dependent claim limitations (claims as provided).

References

[1] US Patent 6,090,799. Claims as provided in the prompt (method for ameliorating HIV-associated myopathy in AIDS patients using orally administered oxandrolone; dosage range 2.5 to 7.5 mg/day; about 2-week duration; dependent scheduling and dosage form limitations).